A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies

Stopped Amgen strategic business decision to cancel following portfolio review, re-prioritization.

Conditions

• Relapsed/Refractory AML
• Minimal Residual Disease Positive AML
• Myelodysplastic Syndrome

Interventions

• DRUG: AMG 330

Sponsor

Amgen